Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.

Published on Jan 1, 2021in Biomaterials10.317
· DOI :10.1016/J.BIOMATERIALS.2020.120381
Javad Garousi13
Estimated H-index: 13
(Uppsala University),
Emma von Witting4
Estimated H-index: 4
(KTH: Royal Institute of Technology)
+ 8 AuthorsSophia Hober41
Estimated H-index: 41
(KTH: Royal Institute of Technology)
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity ProTein). ADAPTs are selected from a library based on the scaffold of ABD (Albumin Binding Domain) of protein G. A particular ADAPT, the ADAPT6, binds to human epidermal growth factor receptor type 2 (HER2) with high affinity. Preclinical and early clinical studies have demonstrated that radiolabeled ADAPT6 can image HER2-expression in tumors with high contrast. However, its rapid glomerular filtration and high renal reabsorption have prevented its use in radionuclide therapy. To modify the biodistribution, ADAPT6 was genetically fused to an ABD. The non-covalent binding to the host's albumin resulted in a 14-fold reduction of renal uptake and appreciable increase of tumor uptake for the best variant, 177Lu-DOTA-ADAPT6-ABD035. Experimental therapy in mice bearing HER2-expressing xenografts demonstrated more than two-fold increase of median survival even after a single injection of 18 MBq 177Lu-DOTA-ADAPT6-ABD035. Thus, a fusion with ABD and optimization of the molecular design provides ADAPT derivatives with attractive targeting properties for radionuclide therapy.
#1Olga Bragina (RAS: Russian Academy of Sciences)H-Index: 4
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 16 authors...
Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. METHODS: Twenty-nine patients with prim...
7 CitationsSource
#1Sergey M. Deyev (Tomsk Polytechnic University)H-Index: 29
#2Anzhelika Vorobyeva (Tomsk Polytechnic University)H-Index: 11
Last. Vladimir Tolmachev (Tomsk Polytechnic University)H-Index: 61
view all 11 authors...
Abstract Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast...
6 CitationsSource
#1Clemens Kratochwil (DKFZ: German Cancer Research Center)H-Index: 54
#2Wolfgang P. FendlerH-Index: 30
Last. Ken HerrmannH-Index: 67
view all 25 authors...
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) is currently undergoing clinical validation. Retrospective observational data have documented favourable safety and striking clinical responses. Recent results from a prospective clinical trial (phase II) hav...
57 CitationsSource
#1Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 10 authors...
Abstract Radionuclide molecular imaging is a promising tool that becomes increasingly important as targeted cancer therapies are developed. To ensure an effective treatment, a molecular stratification of the cancer is a necessity. To accomplish this, visualization of cancer associated molecular abnormalities in vivo by molecular imaging is the method of choice. ADAPTs, a novel type of small protein scaffold, have been utilized to select and develop high affinity binders to different proteinaceou...
5 CitationsSource
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 22
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 9 authors...
Potent and specific fusion toxins consisting of a HER2-binding ABD-derived affinity protein (ADAPT), fused to truncated versions of Pseudomonas exotoxin A
5 CitationsSource
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 11
#2Alexey A. Schulga (RAS: Russian Academy of Sciences)H-Index: 14
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 7 authors...
Radionuclide molecular imaging of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal cancer might be used to stratify patients for HER2-targeted therapy as well as monitor treatment response and disease progression. Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins with favorable properties for molecular imaging. Herein we compared two methods for labeling the anti-HER2 DARPin (HE)3-G3, direct and indirect radioiodination. We hypothesiz...
9 CitationsSource
#1Alessandro Zorzi (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 5
#2Sara Linciano (Ca' Foscari University of Venice)H-Index: 2
Last. Alessandro Angelini (Ca' Foscari University of Venice)H-Index: 18
view all 3 authors...
Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation,...
26 CitationsSource
#1Sergey M. Deyev (National Research Nuclear University MEPhI)H-Index: 29
#2Anzhelika VorobyevaH-Index: 11
Last. Vladimir TolmachevH-Index: 61
view all 13 authors...
Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can be selected for binding to desirable molecular targets. High affinity and small size of DARPins render the ...
13 CitationsSource
#1Allal BoutajangoutH-Index: 17
#2Hanna Lindberg (KTH: Royal Institute of Technology)H-Index: 6
Last. Thomas WisniewskiH-Index: 89
view all 13 authors...
Different strategies for treatment and prevention of Alzheimer’s disease (AD) are currently under investigation, including passive immunization with anti-amyloid beta (Aβ) monoclonal antibodies (mAbs). Here, we investigate the therapeutic potential of a novel type of Aβ-targeting agent based on an affibody molecule with fundamentally different properties to mAbs. We generated a therapeutic candidate, denoted ZSYM73-ABD (16.8 kDa), by genetic linkage of the dimeric ZSYM73 affibody for sequesterin...
7 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have demonstrated very promising features as vectors for radionuclide tumour targeting. Radionuclide imaging of human epidermal growth factor 2 (HER2) expression in vivo might be used for stratification of patients for HER2-targeting therapies. ADAPT6, which specifically binds to HER2, has earlier been shown to have very promising features for in vivo targeting of HER2 expressing tumours. In this study we tested the...
11 CitationsSource
Cited By1
#1Ayman AbouzayedH-Index: 4
#2Hanna TanoH-Index: 1
Last. Anna OrlovaH-Index: 53
view all 10 authors...
The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) to an ABD (albumin-binding domain), we aimed to extend the blood circulation of peptides. The synthesized conjugate DOTA-ABD-RM26 was labelled with indium-111 and evaluated...
1 CitationsSource